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Abstract
Common genetic variants have been recently associated with fasting glucose and insulin levels in white populations. Whether
these associations replicate in pre-diabetes is not known. We extended these findings to the Diabetes Prevention Program, a
clinical trial in which participants at high risk for diabetes were randomized to placebo, lifestyle modification or metformin for
diabetes prevention. We genotyped previously reported polymorphisms (or their proxies) in/near G6PC2, MTNR1B, GCK, DGKB,
GCKR, ADCY5, MADD, CRY2, ADRA2A, FADS1, PROX1, SLC2A2, GLIS3, C2CD4B, IGF1, and IRS1 in 3,548 Diabetes Prevention Program
participants. We analyzed variants for association with baseline glycemic traits, incident diabetes and their interaction with
response to metformin or lifestyle intervention. We replicated associations with fasting glucose at MTNR1B (P,0.001), G6PC2
(P=0.002) and GCKR (P=0.001). We noted impaired b-cell function in carriers of glucose-raising alleles at MTNR1B (P,0.001), and
an increase in the insulinogenic index for the glucose-raising allele at G6PC2 (P,0.001). The association of MTNR1B with fasting
glucose and impaired b-cell function persisted at 1 year despite adjustment for the baseline trait, indicating a sustained deleterious
effect at this locus. We also replicated the association ofMADDwith fasting proinsulin levels (P,0.001). We detected no significant
impact of these variants on diabetes incidence or interaction with preventive interventions. The association of several
polymorphisms with quantitative glycemic traits is replicated in a cohort of high-risk persons. These variants do not have a
detectable impact on diabetes incidence or response to metformin or lifestyle modification in the Diabetes Prevention Program.
Citation: Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, et al. (2012) Effects of Genetic Variants Previously Associated with Fasting Glucose and Insulin
in the Diabetes Prevention Program. PLoS ONE 7(9): e44424. doi:10.1371/journal.pone.0044424
Editor: Giorgio Sesti, Universita Magna-Graecia di Catanzaro, Italy
Received February 1, 2012; Accepted August 3, 2012; Published September 11, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical
centers and the Coordinating Center for the design and conduct of the study, and the collection, management, analysis, and interpretation of the data, through
Award Number U01DK048489. The Southwestern American Indian Centers were supported directly by the NIDDK and the Indian Health Service. The General
Clinical Research Center Program, National Center for Research Resources, and the Department of Veterans Affairs supported data collection at many of the
clinical centers. Funding for data collection and participant support was also provided by the Office of Research on Minority Health, the National Institute of Child
Health and Human Development, the National Institute on Aging, the Office of Research on Women’s Health, the Centers for Disease Control and Prevention, and
the American Diabetes Association. This research was also supported, in part, by the intramural research program of the NIDDK, and by R01 DK072041 to JCF, KAJ
and ARS. PWF was supported by the Swedish Research Council, Novo Nordisk, Swedish Diabetes Association, and the Swedish Heart-Lung Foundation. The
Investigators gratefully acknowledge the commitment and dedication of the participants of the DPP. The opinions expressed are those of the investigators and
do not necessarily reflect the official views of the funding agencies. A complete list of Centers, investigators, and staff can be found in the Appendix. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: JCF has received consulting honoraria from Novartis, Pfizer and Eli Lilly. Bristol-Myers Squibb and Parke-Davis provided medication.
LifeScan Inc., Health O Meter, Hoechst Marion Roussel, Inc., Merck-Medco Managed Care, Inc., Merck and Co., Nike Sports Marketing, Slim Fast Foods Co., and
Quaker Oats Co. donated materials, equipment, or medicines for concomitant conditions. McKesson BioServices Corp., Matthews Media Group, Inc., and the Henry
M. Jackson Foundation provided support services under subcontract with the Coordinating Center. The authors also received funding from the commercial
source Novo Nordisk. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS
ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: dppmail@biostat.bsc.gwu.edu (DPPRG)
" A list of Diabetes Prevention Program Research Group investigators is provided in the Appendix S1.
PLOS ONE | www.plosone.org 1 September 2012 | Volume 7 | Issue 9 | e44424
*
; jcflorez@partners.org (JCF)
Introduction
Glucose homeostasis is tightly regulated. Control of its
variation in non-diabetic individuals is influenced by familial
factors, many of which are presumed to be heritable [1,2]. In
searching for genetic determinants of quantitative glycemic traits,
candidate gene and genome-wide association studies (GWAS)
conducted in populations of European descent have identified
associations of fasting glucose with genetic variants in or near the
genes that encode glucokinase (GCK; [3]), the glucose-6-
phosphatase catalytic subunit (G6PC2; [4,5]) and the melatonin
receptor 1b (MTNR1B; [6,7]). The Meta-Analysis of Glucose and
Insulin-related traits Consortium (MAGIC) recently performed a
global meta-analysis of 21 GWAS cohorts followed by replication
in 26 studies, totaling .122,000 non-diabetic individuals for
fasting glucose and .98,000 non-diabetic individuals for fasting
insulin [8]. These efforts confirmed the GCK, G6PC2 and
MTNR1B associations, and uncovered associations of fasting
glucose with single nucleotide polymorphisms (SNPs) in or near
DGKB, GCKR, ADCY5, MADD, CRY2, ADRA2A, FADS1, PROX1,
SLC2A2, GLIS3, C2CD4B and the type 2 diabetes genes TCF7L2
and SLC30A8. In addition, SNPs in or near IGF1, GCKR and
perhaps IRS1 have been found to influence fasting insulin
concentrations, a surrogate for insulin resistance. Of these loci,
only GCK, MTNR1B, DGKB, GCKR, ADCY5 and PROX1 (besides
TCF7L2 and SLC30A8) were associated with type 2 diabetes at
genome-wide significance levels, with several others (but not all)
showing a consistent trend but not meeting the same stringent
statistical threshold. This work has illustrated that genetic
associations with quantitative intermediate traits may lead to
the discovery of type 2 diabetes loci, but also that not all genetic
loci that influence fasting glucose levels in healthy individuals
necessarily contribute to type 2 diabetes pathogenesis.
The MAGIC investigators have also performed more detailed
characterization of the mechanisms of glucose regulation influ-
enced by these loci in white individuals [9]. In the Third National
Health and Nutrition Examination Survey (NHANES III), a
genetic risk score constructed with the glucose-raising alleles was
shown to have consistent effects in other ethnic groups represen-
tative of the US population [10]. The Gene 6 Lifestyle
interactions And Complex traits Involved in Elevated disease
Risk (GLACIER) investigators showed that several of these loci
associate with impaired fasting glucose (IFG) cross-sectionally and
prospectively, and some have a progressively deleterious effect on
fasting glucose [11]. Shortly thereafter, the Whitehall II investi-
gators reported that a genetic risk score constructed with these
variants was strongly associated with fasting glucose and remained
stable over time [12]. Finally, we have recently shown that
different genetic variants influence type 2 diabetes risk at distinct
stages of the normoglycemia to IFG to type 2 diabetes progression,
with MTNR1B and GCK exerting their effects preferentially in the
normoglycemia to IFG transition [13].
To understand why some loci raise fasting glucose but do not
increase type 2 diabetes risk, it is critical to establish whether their
glucose-raising effects remain evident in the setting of impaired
glucose tolerance (IGT), as glycemic context may modulate the
strength of the genetic effect [13]. Furthermore, the impact of
these loci on the prospective development of diabetes has not yet
been reported. Finally, establishing whether and how distinct
preventive interventions modulate these effects may facilitate the
clinical translation of these findings and illuminate the specific
genes and mechanisms by which these loci affect glycemic
homeostasis. We concentrated on SNPs associated with fasting
glucose, rather than those associated with 2-hour glucose [14],
because 1) the two 2-hour glucose SNPs that are not already
captured by fasting glucose-associated variants (GIPR and VPS13C)
have no detectable impact on type 2 diabetes [15], 2) the
ascertainment of DPP participants by the strict IGT definition is
likely to bias the distribution of 2-hour glucose alleles, 3)
longitudinal changes in 2-hour glucose among carriers of the 2-
hour glucose-raising alleles have already been reported in a better
suited population cohort [16], and 4) evidence obtained by the
MAGIC investigators argues against an interaction of known 2-
hour glucose loci with physical activity or body mass index (BMI)
(Robert Scott, personal communication). We therefore genotyped
the fasting glucose-associated SNPs in the multi-ethnic cohort of
the Diabetes Prevention Program (DPP), and analyzed their
relationships with glycemic measures at baseline and one year, the
development of diabetes, and their potential interaction with
preventive interventions on diabetes incidence.
Methods
The Diabetes Prevention Program
The DPP study design and baseline characteristics of the
participants have been described previously [17,18]. Briefly, the
DPP was designed to test whether intensive lifestyle modification
or pharmacologic interventions with metformin or troglitazone
prevent or delay the onset of diabetes in individuals at high risk.
The trial, conducted from 1996 to 2001 in 27 US-based medical
centers, included 3,234 participants randomized to intensive
lifestyle modification (goal .7% weight loss and .150 min/
week of physical activity), metformin (850 mg twice daily), or
placebo; the fourth arm, comprising 585 additional participants
randomized to troglitazone, was terminated early because of
concerns with hepatotoxicity. For enrollment, participants had
to have a fasting glucose between 95–125 mg/dL and IGT (2h-
glucose between 140–199 mg/dL after a 75-gram oral glucose
tolerance test [OGTT]). Of the total 3,819 DPP participants,
3,548 had DNA and consented to genetic investigation: 56.4%
were of European descent, 20.2% African American, 16.8%
Hispanic, 4.3% Asian and 2.4% American Indian by self-report.
Their mean age was 51 years and mean BMI was 34.0 kg/m2.
The primary endpoint (diabetes incidence, ascertained biannu-
ally and confirmed on a second occasion) was reached in nearly
38% of participants randomized to the placebo arm after a
mean of 3.2 years of follow-up; there was a 58% reduction of
diabetes incidence in the lifestyle intervention group and a 31%
reduction in the metformin group compared to placebo [19].
For the purposes of this study, participants randomized to
troglitazone were excluded, leaving a total of 2,890 individuals
with valid genotypes for analysis. Institutional Review Board
approval was obtained by each participating site, and all
participants included in this report provided written informed
consent for the main study and for subsequent genetic
investigations.
Quantitative Glycemic Traits
We calculated the insulin sensitivity index (ISI) as 22.5/[(fasting
insulin6fasting glucose)/18.01]; the ISI is the reciprocal of insulin
resistance calculated by homeostasis model assessment (HOMA-
IR) [20]. We estimated insulin secretion by the insulinogenic index
using the formula [(insulin at 30 min)-(insulin at 0 min)]/[(glucose
at 30 min)-(glucose at 0 min)]. The oral disposition index (DIo)
was calculated as 1/fasting insulin6 insulinogenic index [21]. We
studied genetic associations with these measures at baseline and at
1 year: we chose one year because changes in weight were most
Fasting Glucose and Insulin Variants in the DPP
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pronounced at that time point, and it contained the highest
number of participants with available measures.
SNP Selection and Genotyping
We genotyped the index SNPs associated with fasting glycemic
traits reported by the MAGIC investigators [8]. Where assay
design failed we selected proxies based on linkage disequilibrium
in the HapMap CEU population: rs573225 for rs560887 in
G6PC2, r2 = 0.961; rs917793 for rs4607517 in GCK, r2 = 1.0; and
rs855228 for rs35767 in IGF1, r2 = 0.915. DNA was extracted
from peripheral blood leukocytes and quantitated as previously
described [22]. Genotyping was carried out by allele-specific
primer extension of multiplex amplified products and detection
using matrix-assisted laser desorption ionization time-of-flight
mass spectrometry on a Sequenom iPLEX platform [23].
Genotyping success rate was $98.5%. Because results for the
two previously known type 2 diabetes genes TCF7L2 and SLC30A8
have been reported elsewhere [22,24,25], they are not presented
here.
Statistical Analyses
We used Cox proportional hazards regression models with
genotype, intervention and their interactions as the independent
variables predicting time to diabetes over mean 3.2 years follow-
up. We adjusted for gender, age at enrollment, ethnicity, treatment
arm, and baseline BMI. For the quantitative glycemic traits, we
employed generalized mixed models to test additive effects of
genotype on baseline log-transformed quantitative traits, and on
the same traits after one year of intervention adjusted for the
baseline value, age, sex, self-reported ethnicity, BMI and treatment
arm. We note that these SNPs have been associated with glycemic
traits at genome-wide levels of significance, and therefore their
prior probability of true effects is many orders of magnitude higher
than the genome average. As our analyses represent further
characterization of each of these established loci, we selected a P
value threshold of 0.05. Finally, we also tested for any evidence of
epistatic interactions between the MTNR1B SNP rs10830963 and
the G6PC2 SNP rs573225, both of which have significant effects
on fasting glucose in the DPP, by including appropriate interaction
terms at baseline and one year.
Results
Baseline Associations
The SNPs genotyped, their chromosomal location, the nearest
gene and their allele frequencies in the five DPP ethnic groups are
shown in Table 1. Allele frequencies were comparable to those
previously reported by MAGIC in Europeans [8] and NHANES
III in non-Hispanic whites, African Americans and US Hispanics
[10].
Table 1. SNPs genotyped and their allele frequencies by ethnic group.
Allele frequencies (%)
SNP Chromosome
Position
(NCBI 36) Nearest gene
Alleles
(effect/other)
White
(n=1,617)
African-
American
(n =592)
Hispanic
(n=475)
Asian
(n =125)
American
Indian
(n =81)
Fasting glucose
rs340874 1 184833918 PROX1* C/T 55.9 19.8 41.2 42.3 35.4
rs573225 2 161653734 G6PC2 A/G 71.7 91.8 85.4 90.3 92.0
rs11708067 3 120438894 ADCY5* A/G 79.4 85.9 77.3 91.2 70.0
rs11920090 3 168087406 SLC2A2 T/A 87.1 67.3 86.6 91.1 94.4
rs2191349 7 14947780 DGKB* T/G 55.7 57.9 48.1 64.0 24.1
rs917793 7 44131132 GCK* T/A 19.5 23.7 32.3 21.6 48.1
rs7034200 9 4244098 GLIS3 A/C 48.9 64.2 57.3 46.0 65.6
rs10885122 10 106670840 ADRA2A G/T 88.0 35.6 84.3 86.8 88.9
rs11605924 11 45579933 CRY2 A/C 49.3 87.0 47.7 68.0 51.9
rs7944584 11 47035421 MADD A/T 71.7 95.0 83.7 90.4 98.1
rs174550 11 57899714 FADS1 T/C 68.0 91.4 43.5 55.2 11.1
rs10830963 11 88799685 MTNR1B* G/C 28.8 9.1 22.7 41.2 24.1
rs11071657 15 39256547 C2CD4B A/G 64.4 86.9 53.7 70.0 37.0
Fasting insulin
rs4675095 2 219495543 IRS1 A/T 93.3 98.5 84.8 85.6 69.1
rs855228 12 99957291 IGF1 T/C 84.3 40.9 76.1 65.4 79.0
Fasting glucose and insulin
rs780094 2 27483120 GCKR* C/T 59.6 81.7 62.2 66.8 88.9
*Loci previously associated with type 2 diabetes at genome-wide levels of statistical significance. The allele previously associated with higher levels of the trait (effect
allele) is shown first; allele frequencies correspond to the effect allele. Gene names: PROX1, prospero homeobox 1; G6PC2, glucose-6-phosphatase, catalytic, 2; ADCY5,
adenylate cyclase 5; SLC2A2, solute carrier family 2, member 2; DGKB, diacylglycerol kinase, beta 90 kDa; GCK, glucokinase; GLIS3, GLIS family zinc finger 3; ADRA2A,
adrenergic, alpha-2A-, receptor; CRY2, cryptochrome 2; MADD, MAP-kinase activating death domain; FADS1, fatty acid desaturase 1; MTNR1B, melatonin receptor 1B;
C2CD4B, C2 calcium-dependent domain containing 4B; IRS1, insulin receptor substrate 1; IGF1, insulin-like growth factor 1; GCKR, glucokinase regulator.
doi:10.1371/journal.pone.0044424.t001
Fasting Glucose and Insulin Variants in the DPP
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Table 2. Nominal genotypic associations with quantitative traits at baseline.
SNP Nearest gene Alleles (effect/other) Trait LS Means (95% CI) Additive P value Pairwise P values
rs573225 G6PC2 A/G FG (mg/dL) AA 106.7 (106.2–107.2) 0.002 AA vs AG 0.002
AG 105.6 (104.9–106.3) AA vs GG 0.31
GG 105.8 (104.5–107.1) AG vs GG 0.73
Fins (mU/mL) AA 24.44 (23.65–25.26) 0.006 AA vs AG 0.31
AG 24.97 (23.87–26.11) AA vs GG 0.005
GG 27.71 (25.56–30.05) AG vs GG 0.02
Ins Index AA 1.25 (1.20–1.31) 0.002 AA vs AG 0.16
AG 1.20 (1.13–1.28) AA vs GG 0.003
GG 1.04 (0.92–1.17) AG vs GG 0.03
ISI AA 0.155 (0.15–0.161) 0.03 AA vs AG 0.62
AG 0.154 (0.147–0.161) AA vs GG 0.01
GG 0.138 (0.127–0.15) AG vs GG 0.03
DIo AA 0.049 (0.047–0.051) ,0.001 AA vs AG 0.03
AG 0.046 (0.043–0.049) AA vs GG ,0.001
GG 0.037 (0.033–0.042) AG vs GG ,0.001
rs11708067 ADCY5 A/G Fins (mU/mL) AA 24.05 (23.24–24.88) 0.001 AA vs AG 0.001
AG 25.85 (24.79–26.95) AA vs GG 0.53
GG 25.29 (23.12–27.67) AG vs GG 0.64
ISI AA 0.158 (0.153–0.164) 0.004 AA vs AG 0.003
AG 0.148 (0.141–0.154) AA vs GG 0.72
GG 0.151 (0.138–0.166) AG vs GG 0.72
rs11920090 SLC2A2 T/A DIo AA 0.042 (0.037–0.049) 0.006 AA vs AT 0.27
AT 0.046 (0.043–0.049) AA vs TT 0.04
TT 0.049 (0.047–0.051) AT vs TT 0.03
rs7944584 MADD A/T Proins (pmol/L) AA 16.4 (15.9–16.92) ,0.001 AA vs AT ,0.001
AT 14.98 (14.34–15.65) AA vs TT ,0.001
TT 13.53 (12.46–14.68) AT vs TT 0.01
rs174550 FADS1 T/C Fins (mU/mL) TT 23.78 (22.83–24.78) 0.008 TT vs CT 0.06
CT 24.97 (23.96–26.03) TT vs CC 0.06
CC 25.52 (24.25–26.86) CT vs CC 0.47
ISI CC 0.149 (0.141–0.157) 0.01 TT vs CT 0.09
CT 0.153 (0.146–0.159) TT vs CC 0.09
TT 0.160 (0.153–0.167) CT vs CC 0.46
rs10830963 MTNR1B G/C FG (mg/dL) GG 108.7 (107.6–109.9) ,0.001 GG vs CG 0.02
CG 107.3 (106.7–108.0) GG vs CC ,0.001
CC 105.6 (105.1–106.2) CG vs CC ,0.001
Proins (pmol/L) GG 15.88 (14.80–17.03) 0.009 GG vs CG 0.66
CG 15.43 (14.85–16.04) GG vs CC 0.66
CC 16.44 (15.90–17.00) CG vs CC 0.003
Ins Index GG 1.17 (1.05–1.29) 0.01 GG vs CG 0.74
CG 1.19 (1.12–1.25) GG vs CC 0.21
CC 1.27 (1.21–1.33) CG vs CC 0.05
rs855228 IGF1 T/C FG (mg/dL) TT 106.1 (105.5–106.7) 0.01 TT vs CT 0.37
CT 106.4 (105.8–107.0) TT vs CC 0.02
CC 107.7 (106.6–108.7) CT vs CC 0.43
rs780094 GCKR C/T FG (mg/dL) CC 106.8 (106.2–107.3) 0.001 CC vs CT 0.12
CT 106.3 (105.6–106.9) CC vs TT 0.003
TT 105.2 (104.3–106.1) CT vs TT 0.04
FG, fasting glucose; Fins, fasting insulin; Ins Index, insulinogenic index; ISI, insulin sensitivity index; DIo, oral disposition index; Proins, fasting proinsulin adjusted for
fasting insulin. To convert glucose mg/dL to mmol/L, divide by 18.01. To convert insulin mU/ml to pmol/L to, multiply by 6.0.
doi:10.1371/journal.pone.0044424.t002
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Table 3. Associations with quantitative traits at one year.
FG Fins Proins Ins Index ISI DIo
SNP Nearest gene
Alleles
(effect/other) P int P assoc P int P assoc P int P assoc P int P assoc P int P assoc P int P assoc
rs340874 PROX1 C/T 0.81 0.47 0.90 0.15 0.99 0.08 0.42 0.99 0.89 0.14 0.63 0.22
rs573225 G6PC2 A/G 0.96 0.17 0.08 0.88 0.34 0.91 0.77 0.20 0.11 0.66 0.81 0.08
rs11708067 ADCY5 A/G 0.80 0.27 0.22 0.98 0.31 0.85 0.46 0.32 0.20 0.80 0.86 0.52
rs11920090 SLC2A2 T/A 0.88 0.49 0.24 0.53 0.79 0.38 0.59 0.98 0.25 0.49 0.69 0.89
rs2191349 DGKB T/G 0.79 0.41 0.04 – 0.09 0.80 0.50 0.55 0.07 0.84 0.84 0.99
rs917793 GCK T/A 0.07 0.12 0.39 0.12 0.08 0.31 0.86 0.23 0.24 0.08 0.42 0.07
rs7034200 GLIS3 A/C 0.72 0.98 0.02 – 0.25 0.56 0.94 0.94 0.03 – 0.13 0.64
rs10885122 ADRA2A G/T 0.82 0.14 0.20 0.60 0.16 0.46 0.29 0.18 0.25 0.44 0.31 0.03
rs11605924 CRY2 A/C 0.20 0.56 0.13 0.46 0.76 0.80 0.40 0.28 0.13 0.40 0.21 0.58
rs7944584 MADD A/T 0.04 – 0.73 0.80 0.63 0.30 0.11 0.10 0.63 0.83 0.36 0.29
rs174550 FADS1 T/C 0.58 0.20 0.87 0.09 0.73 0.23 0.76 0.97 0.86 0.07 0.64 0.65
rs10830963 MTNR1B G/C 0.68 0.003 0.17 0.37 0.27 0.41 0.69 0.002 0.16 0.90 0.96 0.08
rs11071657 C2CD4B A/G 0.04 – 0.96 0.42 0.55 0.97 0.38 0.09 0.98 0.54 0.35 0.048
rs4675095 IRS1 A/T 0.21 0.99 0.67 0.26 0.68 0.59 0.53 0.55 0.71 0.30 0.62 0.62
rs855228 IGF1 T/C 0.39 0.60 0.15 0.27 0.52 0.87 0.36 0.72 0.15 0.24 0.63 0.75
rs780094 GCKR C/T 0.57 0.76 0.07 0.22 0.25 0.38 0.17 0.92 0.09 0.26 0.43 0.28
FG, fasting glucose; Fins, fasting insulin; Ins Index, insulinogenic index; ISI, insulin sensitivity index; DIo, oral disposition index; Proins, fasting proinsulin adjusted for
fasting insulin. P int denotes the P value for the genotype6 intervention interaction test; P assoc denotes the P value for the main effect association in the full cohort
when P int .0.05.
doi:10.1371/journal.pone.0044424.t003
Table 4. Levels of quantitative glycemic traits at one year by genotype and treatment arm at loci with a nominally significant
interaction.
Placebo Metformin Lifestyle
SNP gene
Alleles
(effect/
other) Trait LS Means (95% CI) P values LS Means (95% CI) P values LS Means (95% CI) P values
rs2191349 T/G Fins GG 24.71 (22.96–26.59) GG/GT: 0.99 GG 22.62 (21.02–24.34) GG/GT: 0.21 GG 18.43 (17.03–19.94) GG/GT: 0.99
DGKB (mU/mL) GT 24.99 (23.59–26.48) GG/TT: 0.99 GT 21.30 (20.06–22.62) GG/TT: 0.04 GT 19.01 (17.82–20.28) GG/TT: 0.99
TT 25.71 (24.00–27.54) GT/TT: 0.99 TT 20.41 (19.03–21.88) GT/TT: 0.21 TT 19.05 (17.71–20.51) GT/TT: 0.99
rs7034200 A/C Fins AA 24.86 (23.27–26.55) AA/AC: 0.99 AA 22.54 (21.06–24.12) AA/AC: 0.12 AA 18.01 (16.76–19.36) AA/AC: 0.28
GLIS3 (mU/mL) AC 25.23 (23.83–26.73) AA/CC: 0.99 AC 21.14 (19.87–22.50) AA/CC: 0.05 AC 19.20 (18.02–20.45) AA/CC: 0.28
CC 25.07 (23.18–27.12) AC/CC: 0.99 CC 20.45 (19.00–22.01 AC/CC: 0.37 CC 19.47 (17.96–21.11) AC/CC: 0.74
ISI AA 0.153 (0.142–0.164) AA/AC: 0.99 AA 0.175 (0.163–0.189) AA/AC: 0.14 AA 0.222 (0.205–0.240) AA/AC: 0.28
AC 0.152 (0.143–0.162) AA/CC: 0.99 AC 0.187 (0.175–0.200) AA/CC: 0.06 AC 0.207 (0.193–0.221) AA/CC: 0.28
CC 0.151 (0.139–0.165) AC/CC: 0.99 CC 0.194 (0.179–0.210) AC/CC: 0.36 CC 0.204 (0.186–0.222) AC/CC: 0.74
rs7944584 A/T FG AA 106.8 (105.5–108.1) AA/AT: 0.008 AA 102.4 (101.3–103.5) AA/AT: 0.99 AA 102.1 (101.0–103.2) AA/AT: 0.99
MADD (mg/dL) AT 104.3 (102.6–106.1) AA/TT: 0.50 AT 102.7 (101.1–104.2) AA/TT: 0.99 AT 101.5 (99.98–103.1) AA/TT: 0.99
TT 104.8 (101.4–108.3) AT/TT: 0.78 TT 101.3 (98.45–104.3) AT/TT: 0.99 TT 101.4 (98.65–104.2) AT/TT: 0.99
rs11071657 A/G FG AA 107.1 (105.6–108.7) AA/AG: 0.41 AA 102.3 (101.0–103.6) AA/AG: 0.99 AA 101.9 (100.6–103.2) AA/AG: 0.96
C2CD4B (mg/dL) AG 105.9 (104.5–107.4) AA/GG: 0.41 AG 102.7 (101.4–104.0) AA/GG: 0.99 AG 101.7 (100.4–103.0) AA/GG: 0.96
GG 105.3 (103.1–107.6) AG/GG: 0.63 GG 102.0 (100.2–103.9) AG/GG: 0.99 GG 102.7 (100.8–104.7) AG/GG: 0.96
P values for pairwise comparisons between genotypic groups are shown, with groups separated by a ‘‘/’’. Fins, fasting insulin (mU/mL); ISI, insulin sensitivity index; FG,
fasting glucose (mg/dL). To convert glucose mg/dL to mmol/L, divide by 18.01. To convert insulin mU/ml to pmol/L to, multiply by 6.0.
doi:10.1371/journal.pone.0044424.t004
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We tested associations of these SNPs with baseline fasting
glucose, fasting insulin, fasting proinsulin adjusted for fasting
insulin, the insulinogenic index, the ISI and the DIo in this
multiethnic cohort of individuals with IGT. We replicated
associations with fasting glucose at G6PC2 (P= 0.002),
MTNR1B (P,0.001) and GCKR (P= 0.001). We also replicated
associations of the glucose-raising allele with reduced insulino-
genic index at MTNR1B and increased insulinogenic and
disposition indices at G6PC2. We again noted a strong
association of MADD with fasting proinsulin levels, adjusted
for concomitant insulin (P,0.001). All nominally significant
(P,0.05) associations and corresponding trait distributions are
shown in Table 2.
Figure 1. Effect of genotype atMTNR1B rs10830963 on glycemic traits at baseline and one year. Fasting glucose is shown in panel (a) and
the insulinogenic index is shown in panel (b). Because no significant SNP6 intervention interaction was found, the full cohort was analyzed in
aggregate. Fasting glucose is higher (P= 0.003) and the insulinogenic index is lower (P=0.002) in carriers of the G risk allele after one year, even after
adjustment for the corresponding baseline levels. Least-square means (695% CI) are shown. To convert glucose mg/dL to mmol/L, divide by 18.01.
doi:10.1371/journal.pone.0044424.g001
Table 5. Diabetes incidence by genotype at each locus, in the overall cohort and stratified by treatment arm.
SNP
Nearest
gene Alleles
SNP *
Tx
Treatment
adjusted HR
(95% CI)
P-
value
PLACEBO HR
(95% CI)
P-
value
METFORMIN HR
(95% CI)
P-
value
LIFESTYLE HR
(95% CI)
P-
value
rs340874 PROX1* C (vs T) N 0.88 (0.78–0.98) 0.02 0.85 (0.71–1.01) 0.06 0.92 (0.75–1.12) 0.39 0.86 (0.68–1.08) 0.20
rs573225 G6PC2 A (vs G) N 1.11 (0.97–1.27) 0.14 0.96 (0.77–1.19) 0.70 1.18 (0.94–1.47) 0.15 1.27 (0.98–1.64) 0.07
rs11708067 ADCY5* A (vs G) N 1.06 (0.92–1.23) 0.38 1.04 (0.84–1.28) 0.73 1.08 (0.84–1.35) 0.60 1.10 (0.82–1.47) 0.51
rs11920090 SLC2A2 T (vs A) N 1.02 (0.88–1.19) 0.75 1.08 (0.86–1.33) 0.56 1.00 (0.77–1.30) 0.99 0.99 (0.71–1.37) 0.93
rs2191349 DGKB* T (vs G) N 1.06 (0.94–1.18) 0.34 1.05 (0.88–1.27) 0.56 1.10 (0.90–1.33) 0.34 1.01 (0.80–1.27) 0.96
rs917793 GCK* T (vs A) N 0.96 (0.84–1.10) 0.59 0.87 (0.70–1.07) 0.20 1.14 (0.90–1.44) 0.29 0.92 (0.69–1.22) 0.56
rs7034200 GLIS3 A (vs C) N 1.00 (0.89–1.12) 1.00 0.90 (0.75–1.08) 0.22 1.04 (0.85–1.27) 0.68 1.15 (0.91–1.47) 0.25
rs10885122 ADRA2A G (vs T) N 1.03 (0.91–1.16) 0.63 1.01 (0.84–1.22) 0.89 1.03 (0.84–1.28) 0.76 1.08 (0.84–1.39) 0.56
rs11605924 CRY2 A (vs C) N 1.01 (0.90–1.12) 0.91 0.93 (0.78–1.10) 0.40 1.06 (0.88–1.28) 0.56 1.09 (0.87–1.37) 0.47
rs7944584 MADD A (vs T) N 0.93 (0.80–1.08) 0.29 0.86 (0.69–1.08) 0.20 0.89 (0.69–1.14) 0.35 1.11 (0.84–1.47) 0.47
rs174550 FADS1 T (vs C) N 0.94 (0.83–1.05) 0.26 0.95 (0.80–1.14) 0.57 0.98 (0.80–1.19) 0.81 0.86 (0.67–1.09) 0.21
rs10830963 MTNR1B* G (vs C) N 1.07 (0.94–1.22) 0.29 1.20 (0.98–1.47) 0.07 1.01 (0.80–1.26) 0.95 0.95 (0.73–1.24) 0.69
rs11071657 C2CD4B A (vs G) N 0.93 (0.83–1.05) 0.26 0.93 (0.77–1.12) 0.43 0.92 (0.75–1.14) 0.42 0.96 (0.75–1.22) 0.72
rs4675095 IRS1 A (vs T) N 0.96 (0.78–1.18) 0.68 0.93 (0.67–1.30) 0.69 1.16 (0.84–1.59) 0.37 0.71 (0.44–1.15) 0.17
rs855228 IGF1 T (vs C) N 1.09 (0.97–1.23) 0.14 1.04 (0.87–1.25) 0.66 1.16 (0.95–1.43) 0.15 1.12 (0.88–1.43) 0.38
rs780094 GCKR* C (vs T) N 0.96 (0.85–1.08) 0.48 0.91 (0.75–1.10) 0.33 1.01 (0.82–1.23) 0.93 0.96 (0.75–1.22) 0.72
*Loci previously associated with type 2 diabetes. Effect allele denotes the allele associated with higher glucose or insulin levels in MAGIC. There are no significant SNP6
treatment interactions. One nominally significant P value for association with diabetes incidence is not consistent with the expected direction of effect.
doi:10.1371/journal.pone.0044424.t005
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Associations at One Year
We tested whether the metformin or lifestyle preventive
interventions interacted with each SNP to modulate quantitative
glycemic traits at one year. We adjusted one-year traits for the
corresponding baseline trait, to indicate change in each variable
during active treatment. Where no nominally significant
interaction with treatment was found, SNP main effects on the
one-year trait were tested in the whole cohort with an
adjustment for treatment arm; if an interaction was detected at
P,0.05, analyses were stratified by treatment arm (Table 3).
Nominally significant interactions were found for DGKB and
fasting insulin, GLIS3 and both fasting insulin and ISI, and both
MADD and C2CD4B and fasting glucose. Least-square means for
each genotype group and the corresponding pairwise compar-
isons are shown in Table 4.
At MTNR1B, the glucose-raising allele continued to have a
significant main effect on raising fasting glucose and lowering the
insulinogenic index at one year (Figure 1). Because one-year traits
are adjusted for the baseline level, this effect is indicative of a
worsening deleterious effect of this locus on b-cell function. We
further explored the concordant effects of SNPs at MTNR1B and
G6PC2 on fasting glucose but discordant effects for insulinogenic
index by testing for epistatic interactions between the two on
fasting glucose at baseline and one year: the interaction terms were
not statistically significant.
Diabetes Incidence
We tested whether the metformin or lifestyle preventive
interventions interact with each SNP on the risk of developing
diabetes during 3.2 years of mean follow-up. As no nominal
interactions were found, the effects of each SNP on diabetes
incidence were evaluated in the full cohort while adjusting for
treatment arm; stratified analyses are also shown (Table 5). The
only nominal association with diabetes incidence was found for the
glucose-lowering allele at PROX1 (P=0.02), in a direction opposite
to that reported in case-control analyses in MAGIC, where the C
allele increased type 2 diabetes risk (odds ratio 1.07 [95% CI 1.05–
1.09], P=7.2610210) [8].
Discussion
The MAGIC investigators reported a number of loci that
influence fasting glucose and fasting insulin levels in non-
diabetic populations of European descent; only a few of the loci
were also associated with type 2 diabetes at genome-wide levels
of significance [8]. The authors speculated that it is not the mere
elevation in fasting glucose, but how fasting glucose is raised,
that determines overall b-cell dysfunction and future type 2
diabetes risk. However, whether these loci exert their action on
fasting glucose in the initial stages of diabetes progression (e.g.
from normoglycemia to impaired glucose regulation) or later
(e.g. from IGT to type 2 diabetes) is not known. In the
GLACIER cohort, eleven loci (including the known type 2
diabetes genes TCF7L2 and SLC30A8) were nominally associ-
ated with IFG cross-sectionally, and MTNR1B and G6PC2 were
also associated with development of IFG in longitudinal analyses
[11]. We have recently shown that among type 2 diabetes-
associated loci, risk alleles at MTNR1B, GCK and SLC30A8
confer a stronger rate of progression from normoglycemia to
IFG than from IFG to type 2 diabetes [13]. Here we extend
these findings by testing these SNPs from the IGT to type 2
diabetes transition, and by assessing their effects on quantitative
glycemic traits at baseline and one year in a multiethnic cohort
of persons with IGT.
We have demonstrated that the three loci with the strongest
reported effect on fasting glucose (MTNR1B, GCKR and G6PC2)
have consistent effects in the DPP. All three were known to be
associated with fasting glucose prior to the MAGIC GWAS meta-
analysis [4,5,6,7,26,27,28]. Power may have been limiting to
detect the other reported associations [24].
We have also confirmed that the glucose-raising allele at
MTNR1B is associated with a reduced insulinogenic index, as
measured during the initial phase of insulin secretion during an
OGTT [9,29]. As shown by Lyssenko and coworkers, the
deleterious effects of this allele on b-cell function persist over
time; while they noted such worsening over 24 years of follow-up
[29], here we see such effects over a much shorter time span (one
year). In GLACIER a similar non-significant trend was noted
over 10 years of follow-up [11], although a consistent effect was
not detected in the Whitehall II study [12]. Because MTNR1B
does increase risk of type 2 diabetes [8], this pattern of sustained
deterioration suggests that identifying these individuals early in
their glycemic progression may be beneficial in prevention
efforts.
In contrast, the glucose-raising allele at G6PC2 is associated with
superior b-cell function on dynamic testing; this has been shown
previously [9,30], and is consistent with the role of this gene
product in regulating hepatic glucokinase and its null effect on type
2 diabetes risk [8]. We found no evidence in support of a non-
additive interaction between MTNR1B and G6PC2 on fasting
glucose at baseline or one year. The strong effect of the MADD
locus on fasting proinsulin levels is also confirmed [9,31]; because
this association is adjusted for concomitant insulin levels, it reflects
an increased secretion of insulin precursors out of proportion to
the degree of basal insulin resistance. The other nominal
associations newly reported here do not withstand correction for
the multiple statistical tests performed, and should be considered
hypothesis-generating requiring confirmation in independent
studies.
In summary, the strongest effects of genetic loci on fasting
glucose in non-diabetic individuals of European descent are also
evident in a multiethnic cohort with IGT. The deleterious
influence of the glucose-raising allele at MTNR1B on b-cell
function appears to worsen with time, and this effect is evident in
as short a time as one year. Genetic testing may identify a subset of
patients with IGT more likely to respond to preventive interven-
tions [32].
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